New drug combo aims to shrink tumors before lung cancer surgery

This study is testing whether adding a targeted drug called Bozitinib to standard chemotherapy helps shrink tumors before surgery for people with a specific genetic change (MET-altered) in their stage IIA-IIIC non-small cell lung cancer. The main goal is to see if this combination leads to a 'major pathological response,' meaning very few cancer cells are left in the tumor after it's removed. Researchers will enroll 34 participants who have not had prior cancer treatment and are eligible for surgery.